GlaxoSmithKline PLC said the U.S. Food and Drug Administration approved Benlysta for adult patients with active lupus nephritis receiving standard therapy.
The approval extends the current indication in the U.S. to include both systemic lupus erythematosus and lupus nephritis for the intravenous and subcutaneous formulations.
Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus, the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant, the company said.
https://www.marketscreener.com/quote/stock/GLAXOSMITHKLINE-PLC-9590199/news/GlaxoSmithKline-Benlysta-Gets-FDA-Approval-for-Lupus-Nephritis-32037166/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.